Advancing Diabetes Treatment
Our Capabilities
Pharsight is the largest drug development modeling and simulation company in the world. Having engaged on nearly 350 projects in the past five years, Pharsight Strategic Consulting Services provides expert scientific capabilities to address critical development questions from preclinical testing to post-launch market surveillance. Pharsight resources include seasoned practitioners from industry, government, academia, and consulting. Our multidisciplinary team of more than 20 Ph.D. and MD scientists can optimize your drug development decisions through quantitative exploration of development knowledge and uncertainty that integrates drug/disease models, trial models, and predictive market models.
Leaders in Diabetes Drug Development Consulting
Pharsight has supported more than 12 diabetes development programs for industry clients over the past seven years, from pre-clinical to Phase III. Our consultants have addressed critical issues in trial design, dose selection, and development strategy for the major classes of diabetes therapies, including those with potential for the treatment of glucose and lipid abnormalities associated with Type 2 diabetes and metabolic syndrome. Our recent experience includes modeling and analysis to support Phase IV program strategies, and work with novel mechanisms.
Our extensive knowledge and compilations of public data from the clinical and scientific literature for Type II diabetes mellitus provide a ready context for model-based meta analysis to assess your compound's performance against competing therapies.